Capricor Securities Fraud Class Action
Analysis based on 29 articles · First reported Aug 01, 2026 · Last updated Aug 06, 2026
The revelation of undisclosed statistical analysis plan changes and the subsequent FDA advisory committee vote against Deramiocel's efficacy caused Capricor's stock to plummet by over 75% from its pre-disclosure price, erasing substantial market value. The securities fraud class actions add legal and reputational risk, potentially leading to significant financial penalties and further investor distrust in the company.
Paragon Therapeutics, a biotechnology company developing Deramiocel for Duchenne muscular dystrophy, faces multiple securities fraud class action lawsuits filed by several law firms (Bronstein, Gewirtz & Grossman, Kaplan Fox & Kilsheimer, Bleichmar Fonti & Auld, Schall, Brown & Schwartz) on behalf of investors who purchased CAPR securities between December 17, 2025 and July 26, 2026. The complaints allege that Capricor made false and misleading statements by failing to disclose that it changed the pre-specified statistical analysis plan for Deramiocel's clinical data without prior FDA agreement before resubmitting its Biologics License Application. On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting, revealing these post-hoc changes, causing Capricor's stock to drop 64.5% from $19.70 to $7.00. On July 29, 2026, the FDA advisory committee voted 9-3 that available evidence did not support Deramiocel's efficacy for treating DMD-associated cardiomyopathy, leading to a further 36% stock drop to $4.19. The lawsuits seek to recover investor losses and are pending in the U.S. District Court for the Southern District of California, with a lead plaintiff deadline of September 28, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard